Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease.

BACKGROUND: Data on the serologic status of childhood vaccines, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are limited in inflammatory bowel disease (IBD). Therefore, we evaluated vaccine coverage and seroprotection, along with CMV and EBV seropositivity, in pediatric IBD. METHODS: In a cross-sectional study, demographic data, IBD history, vaccine records, and serum for antibodies against measles, mumps, rubella, diphtheria, tetanus, varicella, hepatitis B (HBV), CMV, and EBV were collected from children with IBD. We evaluated potential factors associated with serologic status. RESULTS: Of 156 subjects, vaccine coverage was up to date for age in 93.5% for measles, mumps, rubella, 95.6% for diphtheria, tetanus, pertussis, polio, hemophilus influenza B, 75.8% for HBV, and 93.5% for varicella, including past infection and vaccination. Seroprotection was present in 65.8% for measles, 60.5% for mumps, 79.1% for rubella, 79.5% for diphtheria, 80.8% for tetanus, 70.5% for varicella, and 62.8% for HBV of subjects. Older age at diagnosis was associated with seroprotection among subjects with complete HBV (odds ratio [OR], 1.20; 95% confidence interval [CI], 1.03-1.39) and rubella series (OR, 1.18; 95% CI, 1.02-1.37). Older age at serum collection was associated with seroprotection among subjects with prior varicella vaccination or infection (OR, 1.69; 95% CI, 1.33-2.15). Only 25.2% and 37.8% demonstrated seropositivity to CMV and EBV, respectively. Among subjects on immunosuppressive medications, 75.3% and 62.4% were seronegative for CMV and EBV, respectively. CONCLUSIONS: Children with IBD have low serologic protection to childhood vaccines in spite of high vaccine coverage and universal vaccinations. Children with IBD, including a large proportion on immunosuppressive medications, have low seropositivity to CMV and EBV.

[Evaluation of an enzyme immunoassay for the determination of the status of immunity against diphtheria before and after vaccination]. / Validierung eines Enzymimmunoassays zur Bestimmung des Diphtherieimmunstatus vor und nach Impfung.

PURPOSE: Assessment of an Easy-to-Perform Immunoenzymatic Assay for Detecting Diphtheria Immunity in the Population. Can an immunoassay replace or support the toxin neutralisation test? SERA AND METHODS: Sera of 75 adults were collected before and after vaccination and tested in the vero cell neutralisation test and the immunoassay. RESULTS: The sensitivity of the EIA was 73 and 94%, specificity was 74 and 67% before and after vaccination, respectively. Positive or negative predictive value was 70 and 96% or 78 and 49% before and after vaccination, respectively. The correlation coefficient changed from 0.43 to 0.77 after vaccination. A comparison of the quantitative results of the test showed differences up to 19 times in individual cases. CONCLUSIONS: Only cases with relatively high antibody titres (e.g. after booster vaccination) show EIA high sensitivity. Linear correlation is also high in such cases. If you expect low antitoxin levels as is the case before booster vaccination, EIA will then often be false positive or negative. Such studies should be limited to the neutralisation method.